Table 4.

Predictors of Mortality and Loss-to-follow-up

	Univariable Analysis	Multivariable Complete Case Analysis	Multivariable Imputed Model
	HR (95 % CI)	HR (95 % CI)	HR (95 % CI)
Gender
Male	1	1	1
Female	0.98 (0.70 – 1.36)	0.70 (0.43 – 1.13)	0.76 (0.53 – 1.10)
Age	0.99 (0.97 – 1.00)	0.99 (0.96 – 1.01)	0.98 (0.96 – 1.00)
ART period
Early (2004 – 2008)	1	1	1
Late (2009–2012)	0.45 (0.32 – 0.64)	0.39 (0.24 – 0.64)	0.40 (0.28 – 0.58)
Baseline CD4 count (cells/μl)
<100	1	1	1
100 – 199	0.78 (0.47 – 1.30)	0.70 (0.34 – 1.42)	0.74 (0.42 – 1.30)
200 – 349	0.81 (0.50 – 1.32)	1.02 (0.50 – 2.09)	0.93 (0.53 – 1.63)
350 – 500	0.62 (0.36 – 1.06)	0.97 (0.45 – 2.10)	1.09 (0.57 – 2.08)
≥500	0.51 (0.27 – 0.97)	0.73 (0.31 – 1.72)	0.78 (0.39 – 1.54)
ACTG KS stage
Good risk	1	1	1
Poor risk	2.37 (1.46 – 3.83)	2.71 (1.53 – 4.79)	1.89 (1.19 – 3.03)
TB Co-morbidity
No TB	1	1	1
TB	1.46 (1.02 – 2.09)	1.26 (0.75 – 2.11)	1.22 (0.83 – 1.81)
ART use
Not on ART at KS diagnosis	1	1	1
On ART at KS diagnosis	0.96 (0.69 – 1.34)	1.09 (0.68 – 1.75)	1.20 (0.84 – 1.72)
Chemotherapy
No	1	1	1
Yes	0.33 (0.24 – 0.47)	0.39 (0.23 – 0.67)	0.35 (0.23 – 0.52)
Radiation Therapy
No	1	1	1
Yes	0.64 (0.47 – 0.89)	0.91 (0.57 – 1.46)	0.64 (0.46 – 0.90)
Haemoglobin	0.86 (0.80 – 0.92)	0.92 (0.83 – 1.02)	0.93 (0.86 – 1.01)

Abbreviations: ACTG: AIDS Clinical Trials Group; ART: antiretroviral therapy; CI: confidence interval; HR: hazard ratio; KS: Kaposi sarcoma; TB: tuberculosis